How Chlamydia Causes Infertility and How to Prevent It

Chlamydia causes infertility primarily by triggering waves of inflammation that scar and block the fallopian tubes, preventing eggs from reaching the uterus. The damage is cumulative: each untreated or repeated infection provokes a stronger immune response, and the scar tissue left behind can be permanent. What makes this process especially insidious is that the majority of chlamydial infections produce no symptoms at all, so the harm often unfolds without any warning until a person tries to conceive and cannot.

Why Most of the Damage Happens Silently

Chlamydia trachomatis infections in the female genital tract are frequently asymptomatic, yet they remain a leading cause of fallopian tube blockage and infertility.¹ Sub-clinical salpingitis, meaning inflammation of the fallopian tubes without noticeable symptoms, is now considered more common than the symptomatic version.² One study found that roughly four in ten asymptomatically infected women had evidence of upper genital tract involvement, which means the infection had already climbed beyond the cervix toward the tubes without producing pain, fever, or unusual discharge.³

This silent progression explains a frustrating pattern clinicians see regularly: there is often a long gap between the original pelvic infection and the moment a person first seeks help for difficulty getting pregnant.² By the time infertility is investigated, the infection itself may have cleared, but the structural damage it left behind remains. In studies of women with tubal factor infertility, researchers frequently find strong antibody responses to chlamydia with no sign of active or ongoing infection, indicating that a past infection caused permanent damage and tubal blockage.⁴

How Inflammation Leads to Scarring

Chlamydia trachomatis has an unusual two-phase life cycle. It exists in an infectious but non-replicating form that invades host cells, then converts into a replicating form inside those cells.⁵ This intracellular lifestyle lets the bacterium hide from the immune system for a time, but eventually infected cells burst open, releasing both new infectious particles and a bacterial heat shock protein. That protein, called cHSP60, acts like a red flag for the immune system, provoking a strong inflammatory response that can damage the very tissue the body is trying to protect.⁶

The fallopian tubes are lined with delicate ciliated cells that sweep eggs toward the uterus. Chlamydial infection causes extensive destruction of these cells, driven in part by a burst of the inflammatory molecule interleukin-1.⁷ As the body fights the infection, it lays down connective tissue to patch things up — essentially creating scar tissue. This fibrosis narrows or completely blocks the tubes, a condition known as tubal occlusion.⁶

There is a troubling molecular wrinkle, too. The chlamydial heat shock protein closely resembles a human heat shock protein. Once the immune system is sensitized to the bacterial version, later exposure to the human version — triggered by other infections or even noninfectious stress — can reactivate the same inflammatory response in the tubes. Over time, this cross-reactive cycle can produce scarring even when chlamydia itself is no longer present.¹

Repeated Infections Make Everything Worse

A single chlamydial episode can cause damage, but the evidence is clear that repeated infections ratchet up the risk. In a primate model designed to mimic what happens in human fallopian tubes, researchers found that by the third infection with chlamydia, the immune response shifted heavily toward a specific type of white blood cell and a pro-inflammatory signaling environment. Fibrosis — the proliferation of scar-forming cells and deposition of connective tissue — was visible by that third infection.⁸

Human data point in the same direction. A large retrospective study found that the risk of pelvic inflammatory disease was higher in women who had two or more positive chlamydia tests compared with those who had only one.⁹ The mechanism is consistent across studies: each round of infection provokes a new immune assault on the tubal lining, and the resulting inflammation and fibrosis are additive. Host factors, hormonal status, age of sexual debut, coinfections, and even pathogen strain differences all influence how quickly or severely the damage accumulates.⁹ Persistent tubal infections are also documented even after courses of antibiotic therapy, which means that treatment failure or inadequate dosing can effectively function like a repeat infection from the body’s perspective.²

The Ectopic Pregnancy Connection

Scarring does not just block eggs. It can also create conditions where a fertilized egg implants inside the fallopian tube instead of reaching the uterus, resulting in an ectopic pregnancy — a life-threatening emergency. Research has identified a specific mechanism for this: chlamydial infection increases the expression of a surface protein called integrin β1 in fallopian tube cells, and that protein makes the tubal lining stickier for embryos. In both human tissue and mouse models, tubes with evidence of prior chlamydia infection showed higher levels of this protein than uninfected tubes. When the protein was blocked in lab experiments, embryo attachment to the infected tubal lining dropped sharply.¹⁰

So chlamydia does not just make it harder to get pregnant; it can make pregnancies that do occur land in the wrong place. Ectopic pregnancies require urgent medical intervention and can damage or destroy the affected tube, compounding the fertility loss further.

Effects on Male Fertility

Men are sometimes left out of conversations about chlamydia and infertility, but the infection affects them too. In men, chlamydia can cause inflammation of the urinary tract and acute epididymitis — swelling of the tube that stores and transports sperm. More directly, one study comparing infected and uninfected men found that the DNA fragmentation index, a measure of sperm DNA damage, was significantly higher in chlamydia-positive cases.¹¹ Damaged sperm DNA makes fertilization less likely and increases the risk of failed embryo development even if fertilization occurs.

Beyond the direct impact on sperm, infected men serve as a reservoir for transmission to female partners, who then face the more severe reproductive consequences described above. Treating and screening both partners is therefore essential to breaking the cycle of reinfection.

When Co-infections Compound the Damage

Chlamydia rarely operates in isolation. It frequently co-occurs with Neisseria gonorrhoeae, the bacterium responsible for gonorrhea. When both infections are present at once, the damage is amplified: studies of the endometrial tissue in co-infected women show greater activation of cell-death pathways and worse suppression of adaptive immune defenses compared to either infection alone.¹² Both pathogens use immune evasion strategies that benefit each other at the host’s expense.¹²

The clinical consequences are visible in population data. In a cohort of young women in remote Australia, having either chlamydia or gonorrhea alone roughly doubled or quintupled the rate of pelvic inflammatory disease compared to having neither. But dual infection carried a risk about four to five times higher than baseline, underscoring how dangerous the combination is.¹³ Mycoplasma genitalium is another co-pathogen of interest: women with tubal factor infertility were roughly four times more likely to carry antibodies to M. genitalium than women with normal tubes, and the presence of both organisms may compound tubal harm.⁴

Screening and Early Detection

Because chlamydia so often causes no symptoms, screening is the primary defense. National guidelines in the United States recommend that sexually active women under age 25 be screened annually for chlamydia.¹⁴ Screening older women is recommended if they have new or multiple sexual partners or other risk factors.

Modern nucleic acid amplification tests, the standard diagnostic method, are highly accurate. On urine samples, one systematic review found pooled sensitivities above 85% for PCR-based methods, and newer platforms push that even higher.¹⁵ These tests can also be run on vaginal or rectal swabs, with sensitivity above 90% from rectal samples on leading platforms.¹⁶ The advantage is that urine-based screening is simple, painless, and can be done at routine check-ups. Stigma around testing remains a real barrier — research shows that younger people and those from lower socioeconomic backgrounds are especially worried about being judged if they accept screening.¹⁷ Normalizing testing as a routine part of sexual health care, rather than something triggered by symptoms or suspicion, helps address this.

Treatment and Antibiotic Choice

Chlamydia is curable with antibiotics, and early treatment before the infection climbs into the upper genital tract is the single most effective way to prevent fertility damage. For years, a one-time dose of azithromycin was the default, prized for its convenience. But evidence has shifted the standard of care. In a head-to-head trial, doxycycline taken over seven days had zero treatment failures, while azithromycin’s single dose failed in about 3% of urogenital cases.¹⁸

The gap is even wider for rectal infections. In a multicenter study of women, doxycycline cured about 96% of rectal chlamydia, compared to roughly 79% for azithromycin. For vaginal infections, the two antibiotics were similarly effective, with cure rates above 93% for both.¹⁹ This matters because rectal chlamydia can go undetected and serve as a source of reinfection even after a vaginal infection appears to be cleared. Current guidelines now favor doxycycline as the first-line treatment for most chlamydial infections.

Speed matters as well. Treating early, before pelvic inflammatory disease develops, limits the immune-driven scarring process. Once significant fibrosis has formed, antibiotics can clear the bacteria but cannot reverse the structural damage to the tubes.

The Role of the Vaginal Microbiome

Your natural vaginal bacteria play a surprisingly active role in defense against chlamydia. A healthy vaginal microbiome dominated by Lactobacillus species produces antibacterial compounds and creates a mechanical barrier that makes it harder for chlamydia to take hold.²⁰ Lab experiments show that vaginal lactobacilli significantly inhibit chlamydia at multiple stages: they damage the infectious particles before they enter cells, reduce how well the bacteria attach to the cell surface, and suppress replication once inside. The degree of protection varies by bacterial strain — some lactobacilli are considerably more effective than others.²¹

Not all Lactobacillus species provide equal protection. Research using a three-dimensional cervical tissue model found that species producing a specific form of lactic acid were associated with long-term protection against chlamydia, while Lactobacillus iners — a common species that lacks this chemical output — was less protective.²² This helps explain why some people with an apparently “normal” vaginal microbiome still get infected: the specific composition matters, not just the presence of lactobacilli in general. Conditions that disrupt vaginal flora — such as frequent douching, certain antibiotics, or bacterial vaginosis — remove this natural barrier and increase susceptibility.

Partner Notification and Preventing Reinfection

Treating only the person who tests positive is one of the most common reasons for reinfection, and reinfection drives cumulative tubal damage. Notifying sexual partners so they can also be treated is critical. One approach that has gained traction is expedited partner therapy, where the diagnosed person’s doctor provides medication or a prescription for their partner without requiring the partner to come in for a separate visit. A community-level trial in Washington State found that this strategy was associated with roughly a 10% reduction in chlamydia positivity in the population, although the confidence intervals were wide.²³ The effect is modest at the population level, but for the individual couple, ensuring both people are treated before resuming sexual contact is the most direct way to prevent a ping-pong cycle of reinfection.

Follow-up testing about three months after treatment is recommended to catch reinfections early, especially for people whose partners may not have been treated or who have new partners.

Chlamydia During Pregnancy

Beyond its effects on fertility, untreated chlamydia during pregnancy can harm the newborn. Transmission to infants during vaginal delivery is well documented, with about 30% to 50% of babies born to mothers with active infection developing neonatal conjunctivitis — a serious eye infection that can lead to scarring if untreated.²⁴ Chlamydial pneumonia in infants is another recognized complication.²⁵ Prenatal screening and treatment eliminate these risks, which is why chlamydia testing is a standard part of early prenatal care in most countries.

Assessing Fertility After a Past Infection

If you have had chlamydia and are now trying to conceive, the question of whether your tubes were damaged is understandably urgent. The standard initial test is hysterosalpingography (HSG), an imaging procedure that pushes dye through the uterus and tubes to check for blockages. It is useful, but it has real limitations. One study found that HSG’s sensitivity for detecting tubal blockage was only about 63%, and for detecting adhesions around the tubes, about 65%.²⁶ That means a normal-looking HSG does not guarantee that the tubes are actually fine, especially in someone with chlamydia antibodies. In that same study, a significantly higher proportion of women whose tubes appeared normal on HSG but were actually blocked on surgical inspection had positive chlamydia antibodies.²⁶

Chlamydia antibody testing itself can be a useful screening tool. One analysis found that a woman with tubal factor infertility was about nine times more likely to have abnormal chlamydia antibody results than a woman without tubal problems, and the test outperformed HSG at predicting tubal disease.²⁷ If antibody tests are positive and you are not conceiving, further investigation with laparoscopy — a minor surgical procedure that lets a surgeon directly visualize the tubes — gives the most reliable picture.

The Search for a Vaccine

Decades of research have gone into developing a chlamydia vaccine, and the effort has finally reached human testing. The first Phase 1 clinical trials have recently been completed, building on years of preclinical work to identify which bacterial proteins trigger the most useful immune response and which delivery platforms and immune-boosting additives are safe enough for clinical use.²⁸ The challenge has always been that chlamydia hides inside cells and that the wrong kind of immune response — the same inflammatory response that causes scarring — can actually make things worse. A successful vaccine would need to stimulate protective immunity without triggering the tissue-damaging inflammation that drives tubal disease.

A working vaccine is still years away from widespread use, if it succeeds at all. But its mere entry into clinical trials marks a significant shift. For now, prevention relies on the combination of consistent condom use, routine screening, prompt antibiotic treatment, and partner notification — imperfect tools, but ones that work when actually used.

Chlamydia and the Uterus

Most attention focuses on the fallopian tubes, but chlamydia can also infect the uterine lining itself. Endometritis, or inflammation of the endometrium, has been identified with chlamydia as the direct cause in cases confirmed by bacterial culture and tissue analysis.²⁹ In a study examining women with abnormal uterine bleeding, chlamydia was detected in nearly half of the specimens, and its presence correlated with significantly higher counts of the immune cells that characterize chronic endometrial inflammation.³⁰ Whether chlamydial endometritis directly impairs embryo implantation is still being studied, but chronic inflammation of the uterine lining is a recognized contributor to implantation failure and early pregnancy loss. The infection’s reach, in other words, extends beyond the tubes alone.

How the Bacterium Can Persist Despite Immune Attack

One of chlamydia’s more alarming traits is its ability to enter a dormant state inside cells when conditions become hostile. When the immune system deploys interferon-gamma, a key signaling molecule meant to starve the bacteria of nutrients, chlamydia can shift into non-replicating “persistent” forms that survive the attack and reactivate later. Recent research using human fallopian tube organoids found that this persistence depends on broader metabolic changes in the host cell than previously thought: the immune signal suppresses a master regulator of cell metabolism, cutting off multiple nutrient pathways at once. When researchers removed the immune signal, chlamydial growth resumed.³¹ This capacity for dormancy and reactivation helps explain why infections can linger in the tubes despite courses of antibiotics, and why damage can continue to accumulate long after a person assumes the infection has been resolved.